Phase 2 N=31 Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 3 N=223 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Phase 2 N=37 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Phase 2 N=151 Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Phase 2 N=10 Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Phase 2 N=41 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
N/A N=17 Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia · Adult Myelodysplastic Syndrome
Primary: Rate of Hospital Admission During Outpatient Induction Chemotherapy — 3; 14 Participants
Phase 2 N=55 Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rate of Complete Remission — 25 patients
Phase 2 N=52 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Phase 2 N=56 Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
Acute Myelogenous Leukemia
Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants
Phase 1 N=17 A Study of LAM-003 in Patients With Acute Myeloid Leukemia
Oncology · Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs
Phase 1 N=9 A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Acute Myeloid Leukemia
Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants
Phase 2 N=172 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Phase 2 N=45 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants
Phase 2 N=74 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 24; 29 participants
Phase 2 N=48 Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Phase 2 N=40 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
AML
Primary: Complete Response Rate — 19 Participants
Phase 2 N=57 A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Phase 2 N=27 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients — 13; 14 Participants — p=<.05
Phase 3 N=485 Trial of Decitabine in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML. — 5.0; 7.7 months — p=0.1079
Phase 2 N=11 Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Leukemia, Myelomonocytic, Acute
Primary: Overall Response Rate (Defined as Partial Remission or Better) to 3 Months of Treatment With Erlotinib — 0 percentage of participants
Phase 3 N=1,645 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia · Leukemia Cutis · Myeloid Neoplasm
Primary: Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations — 45.64; 46.95 percentage of patients
Phase 2 N=36 Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
N/A N=12 Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Syndrome · Myeloproliferative Neoplasm
Primary: Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS — 7 participants
Phase 2 N=27 Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Phase 2 N=111 Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) — 77; 32; 2 Participants
Phase 2 N=175 Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Leukemia · Acute Myeloid Leukemia · AML
Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants
Phase 2 N=47 Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants